Roniel Cabrera

Roniel Cabrera, M.D., M.S.

Medical Director Of Liver Transplant, Section Chief Of Hepatology & Associate Professor

Department: MD-GASTROENTERLOGY-LIVER
Business Phone: (352) 273-9400
Business Email: rcabrera@ufl.edu

Clinical Profile

Specialties
  • Medicine
Subspecialties
  • Gastroenterology
Areas of Interest
  • Autoimmune hepatitis
  • Cirrhosis
  • Gastrointestinal disorders – resources
  • Hepatitis B
  • Hepatitis C
  • Liver biopsy
  • Liver cancer – hepatocellular carcinoma
  • Liver disease
  • Liver disease – resources
  • Liver transplant
  • Primary biliary cirrhosis

Publications

2021
A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC.
Hepatology communications. 5(3):538-547 [DOI] 10.1002/hep4.1652. [PMID] 33681685.
2021
Favorable Survival with Non-curative Treatments for Patients with Early-Stage Hepatocellular Carcinoma After Liver Transplant Denial.
Digestive diseases and sciences. 66(2):628-635 [DOI] 10.1007/s10620-020-06201-w. [PMID] 32219612.
2021
Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate.
European journal of gastroenterology & hepatology. 33(1):102-106 [DOI] 10.1097/MEG.0000000000001700. [PMID] 32243349.
2020
Down staging of hepatocellular carcinoma-can we push the boundaries?
Hepatobiliary surgery and nutrition. 9(4):540-542 [DOI] 10.21037/hbsn.2019.11.14. [PMID] 32832514.
2020
Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation
American Journal of Clinical Oncology-Cancer Clinical Trials. 43(5):325-333 [DOI] 10.1097/COC.0000000000000678. [PMID] 32079854.
2019
Thermal ablation versus wedge or segmental resection in patients with early stage hepatocellular carcinoma: a population survival analysis.
HPB : the official journal of the International Hepato Pancreato Biliary Association. 21(2):249-257 [DOI] 10.1016/j.hpb.2018.07.004. [PMID] 30057124.
2019
Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation.
BioMed research international. 2019 [DOI] 10.1155/2019/7284040. [PMID] 31737675.
2018
Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.
Abdominal radiology (New York). 43(7):1825-1836 [DOI] 10.1007/s00261-017-1354-6. [PMID] 29052747.
2018
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Journal of hepatology. 69(2):353-358 [DOI] 10.1016/j.jhep.2018.04.010. [PMID] 29704513.
2018
Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
Journal of gastrointestinal cancer. 49(2):107-115 [DOI] 10.1007/s12029-018-0065-8. [PMID] 29453759.
2017
Intractable Fasting Hypoglycemia as a Manifestation of Hepatocellular Carcinoma.
Case reports in hepatology. 2017 [DOI] 10.1155/2017/7465025. [PMID] 28785493.
2017
Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chembolization for the Treatment of Hepatocellular Carcinoma.
Current problems in diagnostic radiology. 46(6):402-409 [DOI] 10.1067/j.cpradiol.2017.02.006. [PMID] 28392205.
2017
Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma.
Clinics in liver disease. 21(2):231-251 [DOI] 10.1016/j.cld.2016.12.002. [PMID] 28364811.
2015
Current and future treatments for hepatocellular carcinoma.
World journal of gastroenterology. 21(28):8478-91 [DOI] 10.3748/wjg.v21.i28.8478. [PMID] 26229392.
2015
Transportal Radioembolization as Salvage Hepatocellular Carcinoma Therapy to Maintain Liver Transplant Candidacy.
Journal of vascular and interventional radiology : JVIR. 26(10):1479-83 [DOI] 10.1016/j.jvir.2015.06.029. [PMID] 26408214.
2014
Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
Liver international : official journal of the International Association for the Study of the Liver. 34(9):1428-44 [DOI] 10.1111/liv.12541. [PMID] 24661807.
2013
Another armed CD4(+) T cell ready to battle hepatocellular carcinoma.
Hepatology (Baltimore, Md.). 58(1):1-3 [DOI] 10.1002/hep.26377. [PMID] 23475554.
2013
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.
Liver international : official journal of the International Association for the Study of the Liver. 33(1):72-8 [DOI] 10.1111/liv.12013. [PMID] 23107586.
2013
Hepatic preservation injury: severity of hepatitis C recurrence and survival after liver transplantation.
Digestive diseases and sciences. 58(5):1403-9 [DOI] 10.1007/s10620-012-2521-9. [PMID] 23306846.
2013
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.
Cancer immunology, immunotherapy : CII. 62(4):737-46 [DOI] 10.1007/s00262-012-1380-8. [PMID] 23223899.
2013
Management of liver cirrhosis in patients with hepatocellular carcinoma.
Chinese clinical oncology. 2(4) [DOI] 10.3978/j.issn.2304-3865.2013.09.03. [PMID] 25841913.
2013
Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology. 43(7):757-64 [DOI] 10.1111/hepr.12019. [PMID] 23193965.
2013
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.
Laboratory investigation; a journal of technical methods and pathology. 93(1):8-19 [DOI] 10.1038/labinvest.2012.144. [PMID] 23108376.
2013
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Alimentary pharmacology & therapeutics. 37(1):91-7 [DOI] 10.1111/apt.12098. [PMID] 23094860.
2013
Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma.
Oncology reports. 29(4):1259-67 [DOI] 10.3892/or.2013.2290. [PMID] 23426976.
2012
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics.
Hepatic medicine : evidence and research. 4:19-37 [DOI] 10.2147/HMER.S16316. [PMID] 24367230.
2012
Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation.
American journal of clinical oncology. 35(4):345-50 [DOI] 10.1097/COC.0b013e31821631f6. [PMID] 21552101.
2012
Incidentally Discovered Hcc (Ihcc) in Explant Liver- Clinical and Histopathologic Features and Outcome
Higher Education Policy. 56:476A-477A
2012
Rare case of adult undifferentiated (embryonal) sarcoma of the liver treated with liver transplantation: excellent long-term survival.
Case reports in hepatology. 2012 [DOI] 10.1155/2012/519741. [PMID] 25374706.
2012
Serum Levels of Soluble Cd25 as a Marker for Hepatocellular Carcinoma
Oncology letters. 4(4):840-846 [DOI] 10.3892/ol.2012.826. [PMID] 23205111.
2012
Systemic targeted therapy beyond sorafenib.
Clinical liver disease. 1(6):212-216 [DOI] 10.1002/cld.128. [PMID] 31186890.
2012
The Impact of Pre Transplant Transarterial Therapy in Hepatocellular Carcinoma
Higher Education Policy. 56:458A-459A
2012
The Impact of Pre Transplant Transarterial Therapy in Hepatocellular Carcinoma
Higher Education Policy. 56:458A-459A
2011
A Sustained Viral Response Dramatically Improves Survival in Patients With Hepatitis C Infection After Liver Transplant
. 54
2011
Antiviral Effect of Sorafenib in Hcv Related Hepatocellular Carcinoma
Higher Education Policy. 54
2011
Boceprevir for chronic HCV genotype 1 infection.
The New England journal of medicine. 365(2):176; author reply 177-8 [DOI] 10.1056/NEJMc1105515. [PMID] 21751914.
2011
Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro.
International journal of radiation biology. 87(1):71-80 [DOI] 10.3109/09553002.2010.518208. [PMID] 20958220.
2011
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
Laboratory investigation; a journal of technical methods and pathology. 91(4):598-608 [DOI] 10.1038/labinvest.2010.205. [PMID] 21321535.
2011
Klatskin Tumor- Clinical Outcome and Prognostic Factors
Higher Education Policy. 54
2011
Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
Alimentary pharmacology & therapeutics. 33(2):235-42 [DOI] 10.1111/j.1365-2036.2010.04512.x. [PMID] 21083674.
2011
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Alimentary pharmacology & therapeutics. 34(2):205-13 [DOI] 10.1111/j.1365-2036.2011.04697.x. [PMID] 21605146.
2010
Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25).
Digestive diseases and sciences. 55(2):484-95 [DOI] 10.1007/s10620-009-0955-5. [PMID] 19714465.
2010
Imaging of hepatocellular carcinoma and early diagnosis.
Minerva medica. 101(6):395-404 [PMID] 21196899.
View on: PubMed
2010
Incidence of Hepatocellular Carcinoma in Florida: Distribution in Racial Subpopulations
Higher Education Policy. 52
2010
Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma.
Scandinavian journal of immunology. 72(4):293-301 [DOI] 10.1111/j.1365-3083.2010.02427.x. [PMID] 20883314.
2010
Review article: the management of hepatocellular carcinoma.
Alimentary pharmacology & therapeutics. 31(4):461-76 [DOI] 10.1111/j.1365-2036.2009.04200.x. [PMID] 19925500.
2010
The Impact of Preservation Injury On Accelerated Hepatitis C Recurrence After Liver Transplantation
Higher Education Policy. 52
2010
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study.
Digestive diseases and sciences. 55(1):196-203 [DOI] 10.1007/s10620-009-0981-3. [PMID] 19798576.
2009
Fenofibrate Improves Liver Biochemistries in Primary Biliary Cirrhosis
Higher Education Policy. 50
2009
Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells.
Cell biology international. 33(5):565-71 [DOI] 10.1016/j.cellbi.2009.02.007. [PMID] 19268553.
2009
Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation.
PloS one. 4(11) [DOI] 10.1371/journal.pone.0007980. [PMID] 19956753.
2009
The natural history of hepatitis C cirrhosis after liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 15(9):1063-71 [DOI] 10.1002/lt.21784. [PMID] 19718647.
2009
Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 15(2):216-22 [DOI] 10.1002/lt.21666. [PMID] 19177434.
2008
Cyclosporine Helps To Achieve a Higher Svr in Patients Receiving Peg-Interferon/Ribavirin for Recurrent Hepatitis C After Liver Transplantation: Final Analysis of a Randomized-Controlled Study
. 48 [DOI] 10.1016/S0168-8278(08)60197-X.
2008
Hepatocellular Carcinoma Is Associated With An Impaired Cd4 T Cell Immune Response
. 48 [DOI] 10.1016/S0168-8278(08)60360-8.
2008
Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients With Hepatitis C
American Journal of Transplantation. 8
2008
The Natural History of Hcv-Related Cirrhosis After Liver Transplantation
. 48 [DOI] 10.1016/S0168-8278(08)60003-3.
2008
Using Immune Functional Assay To Differentiate Acute Cellular Rejection From Recurrent Hepatitis C in Liver Transplant Patients
Higher Education Policy. 48
2007
Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells.
Laboratory investigation; a journal of technical methods and pathology. 87(6):582-90 [PMID] 17372588.
View on: PubMed
2007
New Inhibitors of the HCV Life Cycle
Hot Topics in Viral Hepatitis. 7-13
2007
The “C” of viral hepatitis in children.
Seminars in liver disease. 27(3):295-311 [PMID] 17682976.
View on: PubMed
2006
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 12(1):51-7 [PMID] 16382464.
View on: PubMed
2004
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection.
Hepatology (Baltimore, Md.). 40(5):1062-71 [PMID] 15486925.
View on: PubMed
2004
One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 10(10):1240-7 [PMID] 15376304.
View on: PubMed
2003
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.
Hepatology (Baltimore, Md.). 38(4):859-68 [PMID] 14512873.
View on: PubMed

Grants

Sep 2020 ACTIVE
Utilization of Phenotypic Precision Medicine to Identify Optimal Drug Combinations for the Treatment of Hepatocellular Carcinoma
Role: Co-Investigator
Funding: NATL INST OF HLTH NCATS
Mar 2015 – Aug 2018
A Phase 1b, Multi-center, Open-label, Dose Finding Study of CC-122 in Combination with Sorafenib in Subjects with Unresectable Hepatocellular Carcinoma
Role: Principal Investigator
Funding: CELGENE CORP
Apr 2014 – Jul 2018
Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib'
Role: Principal Investigator
Funding: EXELIXIS
Feb 2013 – Feb 2019
Bayer 15982 'A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib'
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Nov 2012 – Nov 2018
'A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy'
Role: Principal Investigator
Funding: DAIICHI PHARMACEUTICAL PHARM CORP

Education

Fellowship – Gastroenterology
2006 · University of Florida
Residency – Internal Medicine
2002 · University of Florida
Medical Degree
2000 · Howard University

Teaching Profile

Courses Taught
2018
MDC6001 Intro Clin Practice

Contact Details

Phones:
Business:
(352) 273-9400
Emails:
Business:
rcabrera@ufl.edu